Media and Communications

News

2002 News Releases

Monday, December 30, 2002
Teva Announces Tentative Approval of Alendronate Sodium Tablets

Jerusalem, Israel, December 30, 2002 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U. S. Food and Drug Administration has granted tentative approval for the company's ANDA for Alendronate Sodium Tablets, 5 mg, 10 mg, 35 mg, 40 mg and 70 mg.Alendronate Sodium Tablets are the generic equivalent of Merck's Fosamax Tablets. The product is indicated for the treatment and prevention of osteoporosis in postmenopausal women and the treatment of Paget's disease. The brand product has annual sales of approximately $1.5 billion.As previously announced, on November 4, 2002, Read More »

Wednesday, December 18, 2002
Teva Announces the Grant of Summary Judgement for Mirtazapine Tablets, Generic Version of Remeron

Jerusalem, Israel, December 18, 2002 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. District Court for the District of New Jersey has granted summary judgment in Teva's favor on the issue of non-infringement with regard to Organon's Remeron® Patent No. 5,977,099. Mirtazapine is the generic version of Remeron ® a monotherapy treatment for depression produced by Organon, a unit of Akzo Nobel. Israel Makov, President and CEO of Teva Pharmaceutical, said: "We are very pleased with the court's decision, which validates our Company's strategy of challenging i Read More »

Friday, December 06, 2002
Teva Shares Now Trading Ex-dividend

Jerusalem, Israel, December 6, 2002 - Teva Pharmaceutical Industries Limited (Nasdaq: TEVA) announced that its ADRs begin trading on a split-adjusted basis earlier today, reflecting its previously announced two for one stock split of its Ordinary Shares/ADRs. The split, which will be effected in the form of a 100% stock dividend, will entitle its holders to one additional Ordinary Share/ADR. Shareholders of record at the close of business on December 10, 2002 will receive one additional Ordinary Share/ADR for each Ordinary Share/ADR held.Certificates for the additional shares/ADRs will be dist Read More »

Thursday, December 05, 2002
Teva Announces Approval of Amoxicillin for Oral Suspension

Jerusalem, Israel, December 5, 2002 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U. S. Food and Drug Administration has approved the company's ANDA for Amoxicillin for Oral Suspension (BID), 200 mg/5 mL and 400 mg/5 mL. A launch date will be determined soon.Amoxicillin for Oral Suspension is the AB-rated generic equivalent of GlaxoSmithKline's broad spectrum antibiotic Amoxil® for Oral Suspension. The brand product has annual sales of approximately $63 million. Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release Read More »

Wednesday, November 27, 2002
Teva Announces Approval of Pergolide Mesylate Tablets

Jerusalem, Israel, November 27, 2002 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has issued final approval for the company's ANDA for Pergolide Mesylate Tablets. This is the first generic approval for Pergolide Mesylate Tablets. The FDA has advised Teva that its application was the first to contain a patent challenge for this product and therefore Teva is entitled to 180 days of marketing exclusivity. Shipments are expected to begin immediately.Pergolide Mesylate Tablets are the AB-rated generic equivalent of Eli Lilly and Com Read More »

Tuesday, November 26, 2002
Teva Confirms Exercise of Option Under Collaboration with Impax Laboratories, Inc.

Jerusalem, Israel, November 26, 2002 - Teva Pharmaceutical Industries Limited (Nasdaq: TEVA) confirmed today that an option relating to an additional product under the strategic alliance between a Teva subsidiary and IMPAX Laboratories, Inc. (Nasdaq: IPXL) has been exercised by Teva.The agreement, signed in June 2001, granted Teva exclusive United States marketing rights and an option to acquire exclusive marketing rights in Canada and various other Western countries for eleven products, allocated among three tiers which reflected the extent of their development at the time of the agreement, p Read More »

Monday, November 25, 2002
Teva Pharmaceutical Industries Ltd Announces a Two for One Stock Split

Jerusalem, Israel, November 25, 2002 - Teva Pharmaceutical Industries, Ltd. (Nasdaq: TEVA) announced today that the Board of Directors has approved a two for one stock split of the Company's Ordinary Shares/ADRs, which will be effected in the form of a 100% stock dividend. Each Ordinary Share/ADR will entitle its holder to one additional Ordinary Share/ADR. Shareholders of record at the close of business December 10, 2002, will receive one additional Ordinary Share/ADR for each Ordinary Share/ADR held.Certificates for the additional shares/ADRs will be distributed by the Company's transfer age Read More »

Thursday, November 21, 2002
Teva Announces Potential Neuroprotection Properties of Copaxone® discovered by Researchers

New Evidence Shows Drug could Protect Patients From Neuronal Loss Jerusalem, Israel, November 21, 2002 - Teva Pharmaceutical Industries, Ltd. (Nasdaq: TEVA) announced today that European researchers have uncovered new evidence that COPAXONE® (glatiramer acetate for injection) not only reduces relapse rate in relapsing-remitting multiple sclerosis (MS) but also encourages the release of a factor that helps protect the brain from axonal loss.According to a study published in the November 2002 issue of Brain, COPAXONE® stimulates T-cells to produce the neuroprotection factor BDNF (brain-derived Read More »

Monday, November 18, 2002
Teva Announces Closing of $450 Million Convertible Debenture Offering

Jerusalem, Israel, November 18, 2002 - Teva Pharmaceutical Industries Limited (Nasdaq:TEVA) is pleased to announce that the initial purchasers of its previously announced convertible debenture offering exercised their option to purchase an additional $75 million of debentures. The offering, which now consists of $450 million in aggregate principal amount of 0.375% Convertible Senior Debentures due 2022 issued by Teva Pharmaceutical Finance B.V., a special purpose finance subsidiary, and guaranteed by Teva, closed earlier today. Lehman Brothers Inc. acted as sole book-running manager for the of Read More »

Wednesday, November 13, 2002
Teva Announces Pricing of $375 Million Convertible Debenture Offering

Jerusalem, Israel, November 13, 2002 - Teva Pharmaceutical Industries Limited (Nasdaq: TEVA) announced today that Teva Pharmaceutical Finance B.V. ("Teva Finance"), a special purpose finance subsidiary, priced its offering of $375 million in aggregate principal amount of 0.375% Convertible Senior Debentures due 2022, guaranteed by Teva. The debentures will be convertible into American Depositary Receipts of Teva at the conversion price of U.S. $85.7978 per ADR (reflecting a premium of 18%, relative to the Nasdaq closing price for Teva's ADRs of U.S. $72.71 on November 12, 2002). The Read More »

​​​